[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641666":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":87,"centralContacts":91,"locations":97,"responsibleParty":343,"collaborators":42,"id":345,"slug":346,"hasResults":347,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":42,"eligibilityCriteria":351,"healthyVolunteers":347,"sex":352,"minAge":353,"maxAge":42,"enrollmentInfo":354,"targetDuration":42,"studyType":357,"phases":358,"briefSummary":361,"conditions":362,"keywords":42,"overallStatus":100,"whyStopped":42,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":373},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: MK-1045 plus Rituximab (or biosimilar)","EXPERIMENTAL","Participants will receive escalating doses of MK-1045 (from 2 mg to 90 mg) once weekly (QW) for up to approximately 12 months. Participants will also receive 375 mg\u002Fm\\^2 rituximab (or biosimilar) once every 4 weeks (Q4W) for up to approximately 6 months.",[13,14,15],"Biological: MK-1045","Biological: Rituximab","Biological: Rituximab biosimilar",{"label":17,"type":10,"description":18,"interventionNames":19},"Part 2: MK-1045 plus Rituximab (or biosimilar)","Participants will receive MK-1045 QW at the dose determined in Part 1 for up to approximately 12 months. Participants will also receive 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q4W for up to approximately 6 months.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Part 2: Physician's Choice of Chemotherapy plus Rituximab (or biosimilar)","Participants will receive physician's choice of: 90 mg\u002Fm\\^2 bendamustine on Days 1 and 2 of each 4-week cycle for up to 6 cycles (up to approximately 6 months) plus 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q4W for up to approximately 6 months OR 750 mg\u002Fm\\^2 cyclophosphamide, 50 mg\u002Fm\\^2 doxorubicin, and 1.4 mg\u002Fm\\^2 vincristine on day 1 of each 3-week cycle (Q3W) and 100 mg\u002Fm\\^2 prednisone (or prednisolone) once daily on days 1 through 5 Q3W for up to 6 cycles (up to approximately 4 months) plus 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q3W for up to approximately 4 months OR 750 mg\u002Fm\\^2 cyclophosphamide and 1.4 mg\u002Fm\\^2 vincristine Q3W and 40 mg\u002Fday prednisone (or prednisolone) once daily on days 1 through 5 of each 3-week cycle for up to 6 cycles (up to approximately 4 months) plus 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q3W for up to approximately 6 months.",[14,15,24,25,26,27,28,29],"Drug: Bendamustine","Drug: Cyclophosphamide","Drug: Vincristine","Drug: Prednisone","Drug: Prednisolone","Drug: Doxorubicin Hydrochloride",[31,38,43,50,58,65,71,77,82],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"BIOLOGICAL","MK-1045","Intravenous (IV) infusion",[9,17],[37],"CN201",{"type":32,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Rituximab","IV infusion",[9,17,21],null,{"type":32,"name":44,"description":40,"armGroupLabels":45,"otherNames":46},"Rituximab biosimilar",[9,17,21],[47,48,49],"TRUXIMA®","RUXIENCE®","RIABNI®",{"type":51,"name":52,"description":40,"armGroupLabels":53,"otherNames":54},"DRUG","Bendamustine",[21],[55,56,57],"Bendeka","Treanda","Belrapzo",{"type":51,"name":59,"description":40,"armGroupLabels":60,"otherNames":61},"Cyclophosphamide",[21],[62,63,64],"Cytoxan","Neosar","Cytophosphane",{"type":51,"name":66,"description":40,"armGroupLabels":67,"otherNames":68},"Vincristine",[21],[69,70],"Oncovin","Vincasar PFS",{"type":51,"name":72,"description":73,"armGroupLabels":74,"otherNames":75},"Prednisone","Per approved product label",[21],[76],"Prednisone acetate",{"type":51,"name":78,"description":73,"armGroupLabels":79,"otherNames":80},"Prednisolone",[21],[81],"Prednisolone acetate",{"type":51,"name":83,"description":40,"armGroupLabels":84,"otherNames":85},"Doxorubicin Hydrochloride",[21],[86],"Adriamycin",[88],{"name":89,"affiliation":5,"role":90},"Medical Director","STUDY_DIRECTOR",[92],{"name":93,"role":94,"phone":95,"phoneExt":42,"email":96},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[98,116,129,139,152,164,179,193,205,217,232,245,256,268,280,294,306,319,331],{"facility":99,"status":100,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":111,"contacts":112},"Duke Cancer Center Clinic 1B\u002FC Onc\u002FHeme ( Site 1307)","RECRUITING","Durham","North Carolina","27710","United States","US",{"type":107,"coordinates":108},"Point",[109,110],-78.89862,35.99403,{"lat":110,"lon":109},[113],{"name":114,"role":94,"phone":115,"phoneExt":42,"email":42},"Study Coordinator","919-681-5698",{"facility":117,"status":100,"city":118,"state":119,"zip":120,"country":104,"countryCode":105,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"SCRI Oncology Partners ( Site 7000)","Nashville","Tennessee","37203",{"type":107,"coordinates":122},[123,124],-86.78444,36.16589,{"lat":124,"lon":123},[127],{"name":114,"role":94,"phone":128,"phoneExt":42,"email":42},"615-329-7640",{"facility":130,"status":100,"city":131,"state":132,"zip":133,"country":134,"countryCode":135,"cosmosGeoPoint":42,"geoPoint":42,"contacts":136},"Instituto Alexander Fleming ( Site 0105)","Ciudad Autonoma de Buenos Aires","Buenos Aires","C1426ANZ","Argentina","AR",[137],{"name":114,"role":94,"phone":138,"phoneExt":42,"email":42},"+541132218900",{"facility":140,"status":100,"city":141,"state":142,"zip":143,"country":134,"countryCode":135,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Sanatorio Nuestra Senora del Rosario ( Site 0104)","Rosario","Santa Fe Province","S2001SBK",{"type":107,"coordinates":145},[146,147],-60.63932,-32.94682,{"lat":147,"lon":146},[150],{"name":114,"role":94,"phone":151,"phoneExt":42,"email":42},"+543414858585",{"facility":153,"status":100,"city":154,"state":42,"zip":155,"country":134,"countryCode":135,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Hospital Privado Universitario de Córdoba ( Site 0102)","Córdoba","X5016KEH",{"type":107,"coordinates":157},[158,159],-64.18853,-31.40648,{"lat":159,"lon":158},[162],{"name":114,"role":94,"phone":163,"phoneExt":42,"email":42},"+54 9 0351 468-8200",{"facility":165,"status":100,"city":166,"state":167,"zip":168,"country":169,"countryCode":170,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Box Hill Hospital ( Site 0201)","Box Hill","Victoria","3128","Australia","AU",{"type":107,"coordinates":172},[173,174],145.12545,-37.81887,{"lat":174,"lon":173},[177],{"name":114,"role":94,"phone":178,"phoneExt":42,"email":42},"+6104438659719",{"facility":180,"status":100,"city":181,"state":42,"zip":182,"country":183,"countryCode":184,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Hadassah Medical Center ( Site 0701)","Jerusalem","9112001","Israel","IL",{"type":107,"coordinates":186},[187,188],35.21633,31.76904,{"lat":188,"lon":187},[191],{"name":114,"role":94,"phone":192,"phoneExt":42,"email":42},"+97226777333",{"facility":194,"status":100,"city":195,"state":42,"zip":196,"country":183,"countryCode":184,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"Sheba Medical Center ( Site 0702)","Ramat Gan","5265601",{"type":107,"coordinates":198},[199,200],34.81065,32.08227,{"lat":200,"lon":199},[203],{"name":114,"role":94,"phone":204,"phoneExt":42,"email":42},"+97235303030",{"facility":206,"status":100,"city":207,"state":42,"zip":208,"country":183,"countryCode":184,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Sourasky Medical Center ( Site 0704)","Tel Aviv","6423906",{"type":107,"coordinates":210},[211,212],34.78057,32.08088,{"lat":212,"lon":211},[215],{"name":114,"role":94,"phone":216,"phoneExt":42,"email":42},"+97236974444",{"facility":218,"status":100,"city":219,"state":220,"zip":221,"country":222,"countryCode":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)","Badalona","Barcelona","08916","Spain","ES",{"type":107,"coordinates":225},[226,227],2.24741,41.45004,{"lat":227,"lon":226},[230],{"name":114,"role":94,"phone":231,"phoneExt":42,"email":42},"34 934978387",{"facility":233,"status":100,"city":234,"state":235,"zip":236,"country":222,"countryCode":223,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Hospital Virgen de la Victoria ( Site 0905)","Málaga","Malaga","29010",{"type":107,"coordinates":238},[239,240],-4.42034,36.72016,{"lat":240,"lon":239},[243],{"name":114,"role":94,"phone":244,"phoneExt":42,"email":42},"34 923291100,56621",{"facility":246,"status":100,"city":220,"state":42,"zip":247,"country":222,"countryCode":223,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Hospital Universitari Vall de Hebron ( Site 0903)","08035",{"type":107,"coordinates":249},[250,251],2.15899,41.38879,{"lat":251,"lon":250},[254],{"name":114,"role":94,"phone":255,"phoneExt":42,"email":42},"+34932746000, 2347",{"facility":257,"status":100,"city":258,"state":42,"zip":259,"country":222,"countryCode":223,"cosmosGeoPoint":260,"geoPoint":264,"contacts":265},"Hospital Universitario Gregorio Maranon ( Site 0902)","Madrid","28007",{"type":107,"coordinates":261},[262,263],-3.70256,40.4165,{"lat":263,"lon":262},[266],{"name":114,"role":94,"phone":267,"phoneExt":42,"email":42},"34 915868888",{"facility":269,"status":100,"city":270,"state":42,"zip":271,"country":222,"countryCode":223,"cosmosGeoPoint":272,"geoPoint":276,"contacts":277},"Hospital Universitario de Salamanca ( Site 0906)","Salamanca","37007",{"type":107,"coordinates":273},[274,275],-5.66388,40.96882,{"lat":275,"lon":274},[278],{"name":114,"role":94,"phone":279,"phoneExt":42,"email":42},"+34923291100ext56621",{"facility":281,"status":100,"city":282,"state":42,"zip":283,"country":284,"countryCode":285,"cosmosGeoPoint":286,"geoPoint":290,"contacts":291},"National Taiwan University Hospital ( Site 1001)","Taipei","10002","Taiwan","TW",{"type":107,"coordinates":287},[288,289],121.52639,25.05306,{"lat":289,"lon":288},[292],{"name":114,"role":94,"phone":293,"phoneExt":42,"email":42},"02-23123456",{"facility":295,"status":100,"city":296,"state":42,"zip":297,"country":284,"countryCode":285,"cosmosGeoPoint":298,"geoPoint":302,"contacts":303},"Chang Gung Medical Foundation-Linkou Branch ( Site 1002)","Taoyuan","333",{"type":107,"coordinates":299},[300,301],121.29696,24.99368,{"lat":301,"lon":300},[304],{"name":114,"role":94,"phone":305,"phoneExt":42,"email":42},"03-3281200",{"facility":307,"status":100,"city":308,"state":42,"zip":309,"country":310,"countryCode":42,"cosmosGeoPoint":311,"geoPoint":315,"contacts":316},"Hacettepe Universite Hastaneleri ( Site 1110)","Ankara","06230","Turkey (Türkiye)",{"type":107,"coordinates":312},[313,314],32.85427,39.91987,{"lat":314,"lon":313},[317],{"name":114,"role":94,"phone":318,"phoneExt":42,"email":42},"+905348719633",{"facility":320,"status":100,"city":321,"state":42,"zip":322,"country":310,"countryCode":42,"cosmosGeoPoint":323,"geoPoint":327,"contacts":328},"Sisli Florence Nightingale Hastanesi ( Site 1112)","Istanbul","34381",{"type":107,"coordinates":324},[325,326],28.94966,41.01384,{"lat":326,"lon":325},[329],{"name":114,"role":94,"phone":330,"phoneExt":42,"email":42},"+905348310606",{"facility":332,"status":100,"city":333,"state":42,"zip":334,"country":310,"countryCode":42,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Ondokuz Mayıs Universitesi ( Site 1113)","Samsun","55270",{"type":107,"coordinates":336},[337,338],36.3361,41.27976,{"lat":338,"lon":337},[341],{"name":114,"role":94,"phone":342,"phoneExt":42,"email":42},"+905068756912",{"type":344,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100641666","phase-2-a-clinical-trial-of-mk-1045-and-rituximab-in-people-with-follicular-lymphoma-mk-1045-007-100641666",false,"NCT07634471","A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","A Phase 2\u002F3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma","Inclusion Criteria:\n\n* Has biopsy-proven, previously untreated, histologically confirmed cluster of differentiation (CD)19-positive and CD20-positive classical follicular lymphoma (FL), with Ann Arbor Stage II-IV disease and a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5.\n* Has radiographically measurable disease per the Lugano Response Criteria.\n* Has provided a newly obtained core or excisional biopsy or archival tissue of a tumor lesion not previously irradiated.\n* If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy (ART).\n* If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks and will continue it.\n* If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.\n\nExclusion Criteria:\n\n* Has received prior systemic anticancer therapy or radiotherapy for FL.\n* Has follicular large B-cell lymphoma or any other subtype of FL other than classical FL.\n* Has FL that has transformed into a more aggressive type of lymphoma.\n* History or presence of clinically relevant central nervous system (CNS) diseases.\n* Has history of serious cardiovascular and cerebrovascular diseases.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known active CNS lymphoma or involvement.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has chronic liver disease, including liver cirrhosis of Child-Pugh class B or C.\n* Has not adequately recovered from major surgery or has ongoing surgical complications.","ALL","18 Years",{"count":355,"type":356},960,"ESTIMATED","INTERVENTIONAL",[359,360],"PHASE2","PHASE3","Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy.\n\nThe goals of this study are to learn:\n\n* About the safety of MK-1045 and rituximab, and if people tolerate them when given together\n* If people who receive MK-1045 and rituximab have the cancer go away\n* If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)",[363],"Follicular Lymphoma","2026-08-20",{"date":366,"type":367},"2026-08-21","ACTUAL",{"date":369,"type":367},"2026-06-22",{"date":371,"type":356},"2035-07-23",{"name":5,"class":6},19]